Tanning Peptides: The Melanocortin Research Behind Melanotan-1 and Melanotan-2

In 1980, a group of chemists in Tucson, Arizona were doing something that sounds comically low-tech: watching frog skin change colour in a dish. They were testing a human hormone, alpha-melanocyte-stimulating hormone, and they had noticed something odd. Boil the hormone in alkali and it stopped behaving normally, working for far longer instead. So they analysed the cooked molecule, found two of its building blocks had flipped their handedness, and rebuilt it deliberately: norleucine at position 4, mirror-image D-phenylalanine at position 7. The result shrugged off the enzymes in blood that normally shred it, and in a mouse melanoma assay it was 26 times as potent as the natural hormone, with what the authors called "ultralong" activity (PMID: 6777774). That molecule is the one research chemists now call Melanotan-1. Nine years later, the same Arizona group bent a shortened version into a ring and produced Melanotan-2.

Those two molecules are what almost everybody means by "tanning peptides", and both sit in our Endocrine & Hormonal research peptides range. This guide explains the biology they were built from: how pigment is actually made inside a skin cell, what the five melanocortin receptors do, why one of these molecules became a licensed medicine for a rare inherited condition while a close relative ended up at a completely different receptor, and what the published studies measured. No melanocortin analogue is approved as a medicine for cosmetic tanning in the UK, the EU or the United States, and the melanocortin compounds Crown Peptides supplies are sold strictly for laboratory research use only.

Why "Tanning Peptide" Is Really a Nickname for a Whole Hormone Family

There is no single thing called a tanning peptide. The term is shorthand for analogues of one hormone, and that hormone belongs to a family with a wide remit: skin colour, adrenal function, appetite, arousal and the glands that waterproof skin and fur.

What alpha-MSH actually is

Alpha-melanocyte-stimulating hormone, usually written alpha-MSH, is a chain of thirteen amino acids: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (PMID: 2555512). It is a peptide hormone in the classic sense, acting on receptors on the outside of its target cells rather than slipping inside them, and our guide to peptide hormones covers how that whole class works.

One precursor, a whole family of messengers

Alpha-MSH is not made from scratch. It is cut out of a much larger protein called pro-opiomelanocortin, or POMC. When a Japanese and American team read the genetic sequence of a cow precursor protein in 1979, they found it contained the stress hormone ACTH, beta-lipotropin and several MSH sequences, with pairs of lysine and arginine separating the components like perforations between stamps (PMID: 221818). Which cutting enzymes a cell carries decides what it makes from that one chain. Hence the family name: melanocortins, because the same precursor yields both the melanin-stimulating peptides and the cortisol-releasing one.

Five receptors, five very different jobs

Here is the fact that explains almost everything about this group of compounds. In 1992, Roger Cone's laboratory at the Vollum Institute in Oregon cloned the mouse and human MSH receptors and a human ACTH receptor, and showed they formed a distinct subfamily of G protein-coupled receptors (PMID: 1325670). Three more followed. Five receptors, MC1R to MC5R, all respond to melanocortin peptides, but sit in different tissues and do different things. A molecule that hits all five is a blunt instrument; one that hits a single receptor is a precision tool. That distinction runs through this whole article.

How Skin Actually Makes a Tan

Before any of the chemistry makes sense, it helps to know what the hormone is talking to.

The cell that does the work

Pigment is made by melanocytes, specialised cells scattered along the base of the epidermis. They build melanin inside small packages and hand those to the surrounding keratinocytes. Pigment driven by MC1R signalling is not melanocytes multiplying; it is existing melanocytes being told to work harder, their pigment distributed through the cells around them.

The switch MC1R throws

MC1R sits on the melanocyte surface. When alpha-MSH binds it, the receptor raises cyclic AMP inside the cell, and a well-mapped chain follows: cyclic AMP activates protein kinase A, which activates the transcription factor CREB, which raises production of a master regulator called MITF, which switches on the pigment genes, including the one for tyrosinase, the enzyme that starts melanin synthesis (PMID: 10841026). The same review notes a counterweight: MAP kinase marks MITF for destruction, so the system is tuned from both ends. Every compound here leans on that one switch, and Melanotan-1 vs Melanotan-2 traces how differently two of them do it.

Two pigments, not one

"Melanin" is really two pigments. Eumelanin, the brown-black one, absorbs ultraviolet light. Pheomelanin, the red-yellow one, has the potential to generate free radicals in response to ultraviolet instead of soaking up the energy (PMID: 7581459). MC1R is the dial that sets the ratio, and it has an opponent: agouti signal protein, which blocks the receptor. In cultured mouse melanocytes, alpha-MSH raised pheomelanin first and only then eumelanin over four days, while agouti signal protein switched the pathway off within a day, in proportion to the fall in tyrosinase protein and activity (PMID: 18627531). The visible lightening needed no existing melanin destroyed; the old pigment was diluted out as the cells turned over.

Why some people freckle instead of tanning

Mammal coat colour turned out to be the same story written in fur. In 1993, Cone's group showed that the mouse "extension" locus, long known to control dark and light coats, is the MSH receptor gene itself: the recessive yellow allele is a frameshift producing a non-functioning receptor, the sombre and tobacco-darkening alleles point mutations producing hyperactive ones. The same locus explains the chestnut horse, the yellow Labrador, the red fox and the black leopard (PMID: 8458079).

Two years later, a Newcastle upon Tyne team found the human version. MC1R gene variants turned up in more than 80% of people with red hair or fair skin that tans poorly, in fewer than 20% of people with brown or black hair, and in less than 4% of those with a good tanning response (PMID: 7581459). Red hair and freckling are, in large part, an MC1R story: a receptor that signals weakly leaves the pigment dial stuck towards pheomelanin.

The sun's own signal

So where does alpha-MSH come from when skin meets sunlight? From the skin itself. In 2007, David Fisher's group at Dana-Farber showed that ultraviolet-induced pigmentation requires keratinocytes to release alpha-MSH, and that the ultraviolet induction of POMC in skin is controlled directly by p53, the tumour-suppressor protein. Mice lacking p53 showed no ultraviolet tanning response at all, and the same POMC chain also yields beta-endorphin (PMID: 17350573). Sunlight damages DNA, p53 responds, and one thing it does is tell the melanocytes next door to start making pigment.

The Two Amino Acids That Changed Everything

Natural alpha-MSH is a hopeless research tool. Blood enzymes clip it apart in minutes, which is exactly what a short-range signal should do and exactly what makes it useless for a controlled experiment. The Arizona group's answer was to find out which bonds the enzymes attacked and make those bonds unrecognisable.

What boiling a hormone revealed

The clue came from an old observation: heat-alkali treatment of alpha-MSH gave it prolonged activity. Quantitative gas chromatography of the treated peptide showed partial racemisation, mostly at the methionine in position 4 and the phenylalanine in position 7 (PMID: 6777774). The harsh treatment had accidentally flipped two amino acids into their mirror-image forms, and that accident was what made the molecule last.

Making the accident deliberate

So the chemists built it on purpose. Position 4's methionine was replaced with norleucine, a similar shape with no oxidisable sulphur. Position 7's phenylalanine was replaced with its mirror image, D-phenylalanine. Enzymes are stereospecific: they recognise the ordinary left-handed amino acids and slide straight past the right-handed ones. The resulting [Nle4, D-Phe7]-alpha-MSH resisted serum enzymes, darkened frog skin, activated adenylate cyclase in mouse melanoma cells at 26 times the potency of alpha-MSH, stimulated tyrosinase activity in those cells, and lasted dramatically longer (PMID: 6777774). The paper's closing hope was modest: a useful molecular probe for studying melanotropin receptors. Our guide to peptide bonds explains why mirror-image residues defeat enzymes so effectively.

Then Someone Closed the Ring

A linear peptide folds almost any way it likes, and most of those shapes are wrong for the receptor. The next move was to lock the active part into the shape that works.

In 1989, Fahad Al-Obeidi, Ana Castrucci, Mac Hadley and Victor Hruby at the University of Arizona used molecular dynamics simulations to design a new class of alpha-MSH analogues, bridging two side chains to form a lactam ring. Seven cyclic peptides were made and tested in standard frog and lizard skin bioassays. In the lizard assay, potencies relative to alpha-MSH ranged from 5 to 100, and the shortened seven-residue version with the ring between aspartate 5 and lysine 10 came in around 90. Rings of 23 and 24 atoms showed prolonged activity; smaller rings did not (PMID: 2555512). That shortened cyclic molecule, Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, is the one now known as Melanotan-II (PMID: 8637402).

Linear versus cyclic, in one paragraph

Melanotan-1 is the full thirteen-residue hormone with two substitutions: same length, same architecture, far tougher, and keeping the parent hormone's receptor profile. Melanotan-2 is a different proposition: a seven-residue fragment with a ring through it, so small and so conformationally fixed that it no longer discriminates well between the melanocortin receptors. One is a reinforced original; the other a rebuilt core. Our comparison, Melanotan-1 vs Melanotan-2, takes that difference apart receptor by receptor, and the individual Melanotan-1 guide and Melanotan-2 guide cover each compound's own study record.

What the Published Human Studies Actually Measured

Both molecules reached human studies in the 1990s, and the published papers are worth reading for what they chose to measure as much as for their results.

A placebo-controlled trial at the University of Arizona

In 1991, a University of Arizona team published a randomised, double-blind, placebo-controlled trial of the linear analogue, which the paper calls NDP-alpha-MSH, in the Journal of the American Medical Association. Twenty-eight healthy white men, recruited from advertisements and paid to take part, were grouped by whether they tanned poorly (skin type I or II) or well (type III or IV). Each received the purified peptide or saline subcutaneously over twelve days and was followed for seven weeks, with a high-potency sunscreen used throughout. The outcome was measured objectively, by serial chromaticity readings: darkening followed a significant parabolic curve in both groups and none occurred on placebo, peaking one to three weeks after the course finished (PMID: 1658407). That curve says something about the biology: the pigment response runs through gene transcription and cell turnover, so it is slow to build and slow to fade.

Why nobody was ever going to make a tablet

A 1997 pharmacokinetic study from the same university compared three delivery routes in three male volunteers, measuring plasma levels by radioimmunoassay. The oral arm produced no detectable drug levels at all, while the parenteral arms were measurable throughout, with a beta-phase plasma half-life of 0.8 to 1.7 hours (PMID: 9113347). That is the ordinary fate of a peptide meeting the digestive system; our article on peptide half-life explains why these numbers vary so much.

The pilot study that accidentally started a different drug

Melanotan-II's first published clinical study, in Life Sciences in 1996, was a single-blind, alternating-day, placebo-controlled pilot in three male volunteers over two weeks. The investigators were looking at pigmentation, and the paper reports it: two of the three showed increased pigmentation in the face, upper body and buttock on quantitative reflectance a week after the course ended. The paper also records what else happened: mild nausea at most levels tested, grade II somnolence and fatigue in one of two volunteers at the top level by World Health Organization criteria, and a stretching and yawning complex coinciding with spontaneous erections (PMID: 8637402). Our Melanotan-2 guide sets that pilot out in full.

That is what a non-selective melanocortin agonist looks like in a study report: pigment from MC1R, nausea and sedation from the brain receptors, arousal from MC4R. Mac Hadley and Robert Dorr's later review records the consequence plainly. Melanotan-I went into clinical study for skin tanning; Melanotan-II was taken forward for erectile dysfunction instead, and a new Melanotan-II analogue, PT-141, was developed by Palatin Technologies (PMID: 16412534). Two destinations, decided by which receptors a molecule could not avoid.

The Branch That Became a Licensed Medicine

The linear analogue's story has a formal ending, and it has nothing to do with cosmetics.

A condition where sunlight is the problem

Erythropoietic protoporphyria is a rare inherited disorder in which a precursor in the haem pathway builds up and reacts to light, so ordinary daylight burns. The trial authors call it a severe photodermatosis with excruciating pain (PMID: 26132941). Under the name afamelanotide, the same [Nle4, D-Phe7]-alpha-MSH sequence was developed as a slow-release implant for exactly that problem: more eumelanin means less light reaching the reacting molecule.

What the registration trials found

The pivotal evidence appeared in the New England Journal of Medicine in 2015: two multicentre, randomised, double-blind, placebo-controlled trials of a subcutaneous implant, one in the European Union with 74 patients and one in the United States with 94, implants every 60 days. The primary endpoint was hours of direct sun exposure without pain. In the US study, median pain-free time after six months was 69.4 hours against 40.8 on placebo (P=0.04); in the EU study, after nine months, 6.0 hours against 0.8 (P=0.005), with phototoxic reactions numbering 77 against 146 (P=0.04). Quality of life improved in both, and adverse events were mostly mild (PMID: 26132941).

Developed separately as a medicine under the brand name Scenesse, afamelanotide is licensed in the European Union, where the European Commission granted marketing authorisation on 22 December 2014 for the prevention of phototoxicity in adults with erythropoietic protoporphyria, and in the United States, where the FDA approved it on 8 October 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from it. That licence belongs to afamelanotide as a finished medicinal product, with its own manufacturing and specialist prescribing arrangements.

The Branch That Ended Up at a Different Receptor

PT-141, now called bremelanotide, is the Melanotan-II analogue that line of work produced. Chemically it is a close relative; pharmacologically it was steered towards MC4R in the brain rather than MC1R in the skin. The FDA approved it on 21 June 2019 as Vyleesi, for acquired, generalised hypoactive sexual desire disorder in premenopausal women in the United States.

The registration evidence was the two identical RECONNECT phase 3 trials, reported in Obstetrics & Gynecology in 2019. Of 1,267 women randomised across the two studies over 24 weeks, those receiving bremelanotide showed statistically significant increases in sexual desire scores (integrated studies 0.35, P<0.001) and reductions in desire-related distress (-0.33, P<0.001) against placebo, with more nausea, flushing and headache (PMID: 31599840). Our PT-141 article covers that programme properly and PT-141 vs Melanotan-2 sets the two side by side; the sequence itself is in our range as PT-141 Research Peptide.

Why Selectivity Is the Whole Story in This Family

Three molecules from one chemistry programme, three different receptors, three different outcomes. So what is sitting at the other four addresses? The cleanest way to find out was to delete each receptor from a mouse and see what broke.

MC4R: the appetite receptor

In 1997, a team led from Millennium Pharmaceuticals inactivated the MC4R gene in mice. The animals developed a maturity-onset obesity syndrome with overeating, high insulin and high blood sugar, reproducing several features of the agouti obesity syndrome and supporting a model in which the agouti protein causes obesity by chronically blocking MC4R (PMID: 9019399). The pigment protein and the appetite receptor turned out to be part of the same conversation.

Analogues show it from the other direction. In a rat study using free-choice diets, Melanotan-II delivered into the brain's lateral ventricle inhibited calorie intake, most strongly in animals on a high-fat diet, and cut the fat component of intake more than the sugar component (PMID: 26733840). A compound people search for as a tanning peptide is, in the rodent literature, a standard tool for studying feeding behaviour; PT-141 vs Melanotan-2 follows that divergence further.

MC3R: the receptor nobody expected to matter

Its neighbour next door turned out not to be a spare copy. In 2000, a Merck group inactivated MC3R in mice and found the opposite of what MC4R had led them to expect: increased fat mass and reduced lean mass with higher feed efficiency, despite the animals eating less than their littermates and having normal metabolic rates. Mice missing both receptors became significantly heavier than mice missing MC4R alone, so the two are not doing the same job (PMID: 10973258).

MC5R: skin and fur, but not pigment

The strangest result came from the receptor nobody has heard of. Cone's group disrupted MC5R in mice and got a severe defect in water repulsion and thermoregulation, traced to reduced sebaceous lipid production; the receptor proved abundant in Harderian, preputial, lacrimal and sebaceous glands (PMID: 9413988). Add those three results together and the shape of the problem is obvious: a compound that cannot tell the receptors apart is talking to oil glands and feeding circuits as well as pigment cells.

What a genuinely selective melanocortin drug looks like

Which is why the family's third licensed medicine matters here. Setmelanotide is an MC4R-targeted agonist developed for severe obesity caused by rare single-gene faults in the melanocortin pathway. In two single-arm, open-label phase 3 trials across ten hospitals in seven countries, 8 of 10 participants with POMC deficiency and 5 of 11 with leptin receptor deficiency reached at least 10% weight loss at about one year, with large falls in hunger scores (PMID: 33137293). It is licensed as Imcivree, authorised in the European Union on 16 July 2021 and first approved by the FDA in November 2020.

And here is the detail that proves selectivity is never absolute: among the most commonly reported adverse events in the POMC trial, alongside reactions at the delivery site, was hyperpigmentation, reported in all ten participants (PMID: 33137293). Aim at MC4R as carefully as current chemistry allows, and MC1R still answers the phone.

The Technical Breakdown: Sequences, Rings and Receptor Pharmacology

For readers who want the molecular detail, here it is. Nothing above depends on this section.

The three sequences side by side

Alpha-MSH is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, acetylated at the front and amidated at the back (PMID: 2555512). The linear analogue keeps all thirteen residues and changes two: norleucine for methionine at position 4, D-phenylalanine for L-phenylalanine at position 7 (PMID: 6777774). The cyclic analogue keeps only residues 4 to 10, substitutes aspartate at 5 and lysine at 10, keeps the D-phenylalanine, and closes a lactam bridge between those side chains to give Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2 (PMID: 2555512, PMID: 8637402).

The message inside the message

Every one of them keeps the same four-residue core: His-Phe-Arg-Trp, with the phenylalanine inverted in both analogues. That short run is what the melanocortin receptors read, which is why a seven-residue fragment can out-perform the full hormone and also why it struggles to tell the subtypes apart. The selective information lives in the residues around the core, and shortening the molecule throws most of it away.

What cyclisation does and does not buy

Rings are not automatically better. A 1997 Uppsala University study measured the binding of five-, six- and seven-residue linear and cyclic MSH core peptides to cells transiently expressing the human MC1, MC3, MC4 and MC5 receptors. Unlike the natural peptides, the core peptides failed to distinguish MC3 from MC4, and every cyclic peptide bound with much lower affinity than its linear counterpart, the loss not depending on ring size (PMID: 9042613). Constraint is a trade: enzyme resistance and a longer-lived shape, at the cost of raw affinity.

The receptors, in atomic detail

Structural biology has now caught up. A 2025 Shanghai study reported cryo-electron microscopy structures of all five human melanocortin receptors, unliganded, each with Gs protein, at resolutions between 2.75 Å and 3.12 Å. Their binding poses closely resembled agonist-bound receptors, fitting the family's unusual baseline activity, and zinc but not calcium positively regulated MC4R in a dose-dependent way (PMID: 40157361). All five couple to Gs and raise cyclic AMP, which is why the chain of events in a pigment cell and in a hypothalamic neuron looks so similar and ends so differently.

Testing a Ring and an Amide: Why Identity Matters Here

Melanocortin analogues are an awkward group to verify, which is precisely why identity testing earns its keep. Both molecules end in an amide rather than a free acid, about one mass unit lighter. One carries a lactam ring whose closure removes a water molecule, about eighteen mass units. A purity percentage cannot see either difference. Weighing the molecule can.

Published analytical work shows how it is done. A Danish and British team validated methods using liquid chromatography with ultraviolet detection at 218 nm plus tandem mass spectrometry, confirming Melanotan-II by retention time and the relative abundance of five qualifying fragment ions from the doubly charged precursor at m/z 513. Applied to vials bought from three online shops, the methods found unknown impurities of 4.1% to 5.9% in material from two of them, and total peptide content of 4.32 to 8.84 mg where 10 mg was claimed (PMID: 24771717). Identity, purity and content are three separate questions.

So both tests travel with every vial we send. Each batch gets its own certificate, carrying an HPLC purity figure and a mass spectrometry identity confirmation, and we publish it on the Lab Reports page under the batch number stamped on your vial, so the two can be read against each other. For a ringed, amidated molecule the mass spectrometry line is the interesting one: Peptide Testing UK explains how the instrument gets there, How to Read a Peptide Certificate of Analysis walks the certificate line by line, and How to Tell If Peptides Are Real is the practical version.

Everything leaves as dry powder, cold and sealed. Order on a weekday before 2pm and it ships that day; UK delivery costs nothing over £100. Certificate questions are the quickest kind to answer, and our contact page carries the WhatsApp number as well as the email.

Related Compounds Worth Knowing About

The melanocortin system touches pigment, appetite, arousal and the skin's own glands, so its nearest neighbours in a research range come from several directions.

The melanocortins themselves

Melanotan-1 is the linear, full-length analogue; Melanotan-2 is the shortened cyclic one that reaches across the family; and PT-141 is the Melanotan-II descendant redirected towards MC4R. All three sit in our Endocrine & Hormonal research peptides category.

Other hypothalamic and pituitary peptide analogues

POMC is only one of the precursors the brain cuts into working hormones, and the same trick of building a tougher copy runs through all of them. Gonadorelin Acetate is synthetic GnRH (see What Is GnRH?), Kisspeptin-10 the active tail of the peptide above it (our Kisspeptin-10 article), and Oxytocin Acetate the nine-residue hormone unchanged (Oxytocin guide). Sermorelin and Tesamorelin are trimming and capping applied to GHRH.

Skin research that has nothing to do with pigment

If the interest is skin biology rather than melanin, the copper peptides are the obvious neighbours. GHK-Cu is the best-studied, explained in our GHK-Cu guide, with AHK-Cu its close relative and SNAP-8 coming at skin from the neuromuscular side. Glutathione is a tripeptide with a genuine link to melanin chemistry, the same tyrosinase step this article has been circling, and our comparison GHK-Cu vs Glutathione sets out how differently the two behave. The three-peptide GLOW Research Peptide blend covers tissue repair, and all of these sit in the Ageing & Cellular Research Peptides category.

Wider reading

For the ground floor, start with What Are Peptides? For skin research generally, see our skin, hair and nails guide and Collagen Peptides vs Copper Peptides; for shelf life, How Long Do Peptides Last?

Five Receptors, and the Chemistry Is Only Just Getting Precise

Look back over forty-five years of this field and the same problem keeps reappearing in new clothes. One ancient motif, His-Phe-Arg-Trp, is read by five receptors scattered across the skin, the adrenal glands, the brain and the body's oil glands. Every analogue ever built has tried to speak to one of them without the others overhearing, and until recently chemists worked half blind, inferring receptor shape from how frog and lizard skin responded.

That has changed. All five human melanocortin receptors have now been solved by cryo-electron microscopy in a single study, with their baseline activity and even their ion sensitivity mapped (PMID: 40157361). Patient structure-activity work produced a genuinely MC4R-directed medicine, and the new structures give the next round of chemistry something earlier designers never had, with MC5R barely explored.

If melanocortin signalling is where your own work is heading, the two molecules that opened it are on the shelf: Melanotan-1 Research Peptide, the full-length original, and Melanotan-2 Research Peptide, the ringed core, with their relatives a click away under Endocrine & Hormonal Research Peptides.

References

• Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77:5754-8. PMID: 6777774
• Al-Obeidi F, Castrucci AM, Hadley ME, et al. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. 1989;32:2555-61. PMID: 2555512
• Nakanishi S, Inoue A, Kita T, et al. Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature. 1979;278:423-7. PMID: 221818
• Mountjoy KG, Robbins LS, Mortrud MT, et al. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992;257:1248-51. PMID: 1325670
• Buscà R, Ballotti R. Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res. 2000;13:60-9. PMID: 10841026
• Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet. 1995;11:328-30. PMID: 7581459
• Le Pape E, Wakamatsu K, Ito S, et al. Regulation of eumelanin/pheomelanin synthesis and visible pigmentation in melanocytes by ligands of the melanocortin 1 receptor. Pigment Cell Melanoma Res. 2008;21:477-86. PMID: 18627531
• Robbins LS, Nadeau JH, Johnson KR, et al. Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell. 1993;72:827-34. PMID: 8458079
• Cui R, Widlund HR, Feige E, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 2007;128:853-64. PMID: 17350573
• Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266:2730-6. PMID: 1658407
• Ugwu SO, Blanchard J, Dorr RT, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos. 1997;18:259-69. PMID: 9113347
• Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58:1777-84. PMID: 8637402
• Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27:921-30. PMID: 16412534
• Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015;373:48-59. PMID: 26132941
• Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134:899-908. PMID: 31599840
• Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997;88:131-41. PMID: 9019399
• Chen AS, Marsh DJ, Trumbauer ME, et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet. 2000;26:97-102. PMID: 10973258
• Chen W, Kelly MA, Opitz-Araya X, et al. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell. 1997;91:789-98. PMID: 9413988
• van den Heuvel JK, Eggels L, van Rozen AJ, et al. Inhibitory Effect of the Melanocortin Receptor Agonist Melanotan-II (MTII) on Feeding Depends on Dietary Fat Content and not Obesity in Rats on Free-Choice Diets. Front Behav Neurosci. 2015;9:358. PMID: 26733840
• Clément K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8:960-970. PMID: 33137293
• Schiöth HB, Muceniece R, Larsson M, et al. Binding of cyclic and linear MSH core peptides to the melanocortin receptor subtypes. Eur J Pharmacol. 1997;319:369-73. PMID: 9042613
• Feng W, Zhou Q, Zheng C, et al. Structural basis for the constitutive activity of the melanocortin receptor family. Structure. 2025;33:1074-1087.e5. PMID: 40157361
• Breindahl T, Evans-Brown M, Hindersson P, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015;7:164-72. PMID: 24771717
• European Medicines Agency. Scenesse (afamelanotide): European public assessment report. EMA
• European Medicines Agency. Imcivree (setmelanotide): European public assessment report. EMA